Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ZymoGenetics
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Diagnosis of CD20+ B-cell NHL

• Disease measurable by computed tomography (CT) scan

• Has failed at least one prior systemic therapy for NHL

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate hepatic and renal function

• Adequate bone marrow function

Exclusion Criteria:

• Presence of acute infection or other significant systemic illness

• White blood cell (WBC) count > 50,000/mm3 in peripheral blood

• Central nervous system involvement by malignancy

• Previous allogenic transplant or autotransplant within 6 months of enrollment

• Other current malignancy or known history of cancer within 5 years

• Received systemic corticosteroids, chemotherapy, immunotherapy, biologic therapy, antibody therapy (e.g., rituximab), radiation therapy, and/or investigational agent(s) within 1 month of enrollment